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 ABSTRACT 
Cancer is a major public health problem and to date cancer is one of the leading causes of 
death worldwide. Neuroblastoma is a malignant pediatric tumor of the sympathetic nervous 
system. Neuroblastoma is one of the most common and deadliest extra cranial tumors of 
childhood. During the last decades, the survival rate has increased for children with 
neuroblastoma. However, this mainly accounts for children with favorable tumor biology 
while only 40-50% of children with high-risk neuroblastoma survive their disease despite 
very intensive treatment regimen. This demands a better understanding of high-risk 
neuroblastoma biology to enable novel therapeutic approaches. 
Solid tumors are composed by a variety of cellular components including malignant cells and 
non-transformed stromal cells. The complex interaction between these cells creates the tumor 
microenvironment and contributes to tumor growth and initiation. Prostaglandin E2 (PGE2) 
regulates tumor inflammation and immune suppression, angiogenesis, metastasis, tumor 
progression and therapy resistance.  
PGE2 production is conducted via the conversion of arachidonic acid (AA) by the 
cyclooxygenase enzymes (COX-1 and COX-2) into the intermediate prostaglandin H2 
(PGH2), subsequently converted by microsomal prostaglandin E synthase-1 (mPGES-1), the 
terminal enzyme responsible for induced PGE2 formation. Inhibitors of the COX enzymes are 
potent preventive agents in several malignancies. However, clinical use of COX inhibitors in 
oncology has been hampered due to side effects caused by unselective inhibition of all 
products downstream of PGH2 that are important for normal cellular functions. In this thesis 
we improve the biological understanding of PGE2 in neuroblastoma and investigate if 
inhibition of mPGES-1 in neuroblastoma could maintain the anti-carcinogenic effect of COX 
targeting without the severe side effects. 
Investigation of neuroblastoma tissues and cell lines revealed an abundant expression of all 
PGE2 receptors and PGE2 increased neuroblastoma cell growth and induced activation of 
survival signaling cascades. Inhibition of PGE2 receptor signaling reduced cell survival. 
Investigation of aggressive high-risk neuroblastoma subsets revealed a highly activated PGE2 
synthesis pathway with elevated levels of PGE2 in tumors due to high mPGES-1 expression 
and low expression of 15-PGDH, responsible of PGE2 degradation. Compared to adult 
malignancies little is known of the role of inflammation in childhood cancers. Analysis of the 
microenvironment of the high-risk tumors showed a higher infiltration of immunosuppressive 
macrophages compared to low-risk tumors indicating a tumor-promoting inflammatory local 
milieu. Furthermore, we could show that infiltrating cancer-associated fibroblasts (CAFs) in 
the neuroblastoma microenvironment was the major source of mPGES-1 expression. 
Pharmacological inhibition of mPGES-1 in preclinical in vivo models modulated the 
microenvironment towards a less tumor-promoting state and significantly reduced tumor 
growth. In an established in vitro model recapitulating in vivo features of neuroblastoma, 
inhibition of mPGES-1 augmented the cytotoxic effect of conventional chemotherapeutics. 
In this thesis it is concluded that mPGES-1 targeting represents a promising novel therapy in 
neuroblastoma. Further, the importance of deepened understanding of the complex 
interactions and heterogeneity within the neuroblastoma microenvironment is underlined.  
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AA Arachidonic acid 
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GD2                              Disialoganglioside 2 
GM-CSF                       Granulocyte macrophage colony stimulating factor 
GPCR                            G-protein coupled receptors  
IL                                   Interleukin 
INFγ                              Interferon γ 
 LPS                               Lipopolysaccharide  
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TGF-β                             Transforming growth factor β 
TNFα                              Tumor necrosis factor α 
TXA2                               Thromboxane  
VGEF                              Vascular endothelial growth factor  
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1 INTRODUCTION 
1.1 CANCER 
Cancer is a group of diseases where cells of the body have transformed into abnormal cells 
that grow without control and have the ability to invade nearby tissues and spread to other 
parts of the body.  
The development of cancer is thought of as a multi-step evolutionary process on the cellular 
level where cancer cells gain somatic gene mutations over time resulting in lost responses to 
normal signals that otherwise strictly controls cell growth and cell death. In the year 2000 
Hanahan and Weinberg described six common traits that together is essential for cancer 
formation and progression; limitless replicative potential, self-sufficient in growth signals, 
insensitivity to anti-growth signals, sustained angiogenesis, evading apoptosis, and tissue 
invasion and metastasis (Hanahan and Weinberg, 2000). Besides proliferating cancer cells a 
tumor is composed of a diverse variety of stromal cells and the extracellular matrix, together 
constituting the tumor microenvironment. The non-malignant cells of the microenvironment 
function not only as a supportive structure but are actively contributing to cancer 
development and progression. Therefore, to fully understand tumorigenesis it is not enough to 
solely study the transformed cancer cells of the tumor (Bissell and Radisky, 2001; Hanahan 
and Weinberg, 2011; Kenny et al., 2007). 
Childhood cancers and cancers that develop in adults differ. Adult cancers develop over a 
long period of time and can often be coupled to lifestyle or environmental exposure. The long 
latency for cancerous development in adults is due to the accumulation of mutations required 
to overcome the normal cellular controls (Knudson, 1971). On the contrary childhood cancers 
are due to defects in the normal development machinery and fewer genetic changes are 
needed for tumor development (Scotting et al., 2005). 
 To date cancer is a leading cause of death worldwide and is a major public health problem 
(Ferlay et al., 2015; Torre et al., 2015). The cancer incidence in Sweden is 60000 persons per 
year and it is constantly increasing(cancerfondsrapporten, 2017). Children diagnosed with 
cancer in Sweden is approximately 300 per year and cancer is the leading cause of death in 
children <15 years of age in Sweden (Barncancerfonden, 2017). The treatment regimens 
today for both adults and children are mainly based on surgery, irradiation and chemotherapy 
in different combinations. Today nearly 80% of children with cancer can be cured 
(Barncancerfonden, 2017). However, for the majority of childhood cancers the survival has 
almost been unchanged during the last 20 years. This suggest that the impact of the 
conventional treatments on survival have reached a plateau (Figure 1) (Gustafsson et al., 
2013; Johnsen et al., 2009) In addition, radiation and chemotherapy are especially hazardous 
in children as they damage the normal developing organs. New innovative therapeutic 
approaches are therefore needed.  
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1.2 NEUROBLASTOMA 
Neuroblastoma is a malignant tumor of the sympathetic nervous system that mainly affects 
young children below one year of age. Neuroblastoma represents 7% of all childhood 
malignancies and accounts for 10% of cancer related deaths of young children (Johnsen et al., 
2009; Park et al., 2014). This makes neuroblastoma the most common and deadliest extra 
cranial cancer in children. Neuroblastoma is a heterogeneous disease, with an extreme 
diversity in clinical presentation and prognosis ranging from spontaneous regression to 
metastatic aggressive tumors with poor prognosis (Brodeur, 2003; Matthay et al., 2016). 
During the last decade the survival of children with neuroblastoma has improved (Figure 1) 
(Gustafsson et al., 2013). However this mainly account for low-risk patients while patients 
with high-risk disease still have a poor prognosis with long term survival rates less than 50% 
in most populations despite intensive therapy (Maris, 2010; Park et al., 2014).  
 
 
Figure 1. The estimated prognosis (5-years survival) over time for selected diagnostic groups. The 
prognosis improved considerably during time period 1970-1995. The results during the last decades seem 
to have reached a plateau. Reprinted from with permission from authors (Gustafsson et al., 2013). 
  3 
  
 
1.2.1 Biology and genetics 
Neuroblastoma was first described as cancer of the developing, immature neural cells called 
neuroblasts in the 1800s by the German pathologist Rudolf Virchow and has since then 
fascinated clinicians and researchers due to its heterogeneous clinical presentations (Virchow, 
1864). Neuroblastoma is thought to originate from neural crest cells, transient multipotent 
cells derived from the ectodermal germ layer that give rise to the peripheral nervous system 
(Knecht and Bronner-Fraser, 2002).The primary tumors are predominantly found in the 
adrenal medulla (65%) but can arise anywhere in the sympathetic nervous tissue along the 
spinal cord (Figure 2) (Brodeur, 2003; Cheung and Dyer, 2013; Maris, 2010). Some 
neuroblastomas have the extraordinary ability to spontaneously mature and regress. The 
mechanism of spontaneous regression is not fully understood but expression of TrkA, lack of 
TERT expression and host antitumor immunity has been suggested to have a role in tumor 
regression (Brodeur and Bagatell, 2014; Matthay et al., 2016). 
Several genetic aberrations have been linked to neuroblastoma. The most common genetic 
alteration related to neuroblastoma includes neuroblastoma MYC (MYCN) oncogene 
amplification, and segmental chromosomal deviations such as 11q deletion, 17q gain and 1p 
deletion (Caren et al., 2010). The correlation of MYCN and advanced stages of 
neuroblastoma was discovered in the 1980s (Brodeur et al., 1984; Schwab et al., 1983). 
Amplification of MYCN, located on the short arm of chromosome 2 is one of the most 
frequent genetic deviation among high risk neuroblastomas, observed in approximately 30-
40% of these patients and has routinely been used as biomarker for treatment stratification 
(Maris et al., 2007). Allelic loss of 1p36 is found in 20-30% of neuroblastomas and correlates 
with MYCN-amplification and poor outcome (Maris et al., 2007). Gain of 17q is the most 
common genetic alteration, found in more than 60% of all neuroblastomas and is often 
Figure 2. Neuroblastoma primary tumors 
derived from the neural crest arise in the 
sympathetic nervous system including the 
adrenal medulla, sympathetic ganglia and 
paraganglia. Neuroblastomas mainly 
metastasize to lymph nodes and bone 
marrow, and in infants also spread to liver 
and subcutaneous tissue. Reprinted with 
permission of Springer Science media and 
Business Media. (Johnsen et al., 2009) 
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detected in advanced tumors in children >1 year of age and is strongly associated with 1p-
deletion and MYCN-amplification (Bown et al., 1999). Another common genetic alteration 
regularly found associated with poor prognosis in neuroblastoma is the segmental deletion of 
the long arm of chromosome 11 (11q-deletion). 11q-deletion commonly occurs in tumors 
with chromosome instability and are almost exclusively lacking MYCN-amplification and is 
therefore a useful predictive marker in unfavorable tumors without MYCN-amplification 
(Caren et al., 2010). Patients with 11q-deletion are often older at disease onset, 42 months 
compared to 21 months in children with MYCN amplified tumors, and have a slower disease 
progression but frequently develop therapy resistance. Patients with 11-q deleted tumors have 
similarly poor clinical outcome as the patients with MYCN amplified tumors (Figure 3) 
(Caren et al., 2010; Cetinkaya et al., 2013). It is clear that 11q-deletion and MYCN-
amplification characterize two distinct groups of aggressive neuroblastoma and that a high 
frequency of 17q gain occurs in both of these groups. Neuroblastomas presented with only 
numerical chromosomal alterations show an excellent overall survival (Caren et al., 2010).  
Hereditary neuroblastoma is rare and accounts only for 1-2% of all neuroblastoma cases. 
Paired–like homeobox 2b (PHOX2B) was the first predisposition mutation found in 
neuroblastoma, however only a small part of hereditary neuroblastoma could be explained by 
PHOX2B mutations. In 2008 it was reported that germ line mutations resulting in a 
constitutive activation of the anaplastic lymphoma kinase (ALK) was the main cause of 
familial neuroblastoma (Mosse et al., 2008). ALK-activating mutations was also found to be 
somatically acquired (Chen et al., 2008; George et al., 2008; Mosse et al., 2008). Both 
PHOX2B and ALK are involved in the development of the nervous system. 
 
 
 
 
Figure 3. Kaplan-Meier overall 
survival for patients with tumors with 
different genomic profiles. The tumors 
are grouped as follows: the other 
segmental group (red line), the 
numerical-only group (blue line), the 
17q-gain group (violet line), the 
MYCN-amplification group (yellow 
line), and the 11q- deletion group 
(green line). Reprinted with permission 
from Proceedings of the National 
Academy of Sciences of the United 
States of America. (Caren et al., 2010) 
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1.2.2 Staging, risk classification and treatment 
The International Neuroblastoma Risk Group staging system (INGRSS) was developed as a 
new staging system in 2009 and is based on tumor imaging to stratify patients at the time of 
diagnosis before treatment instead of post-surgical evaluation. Centered on image-defined 
risk factors (IDRFs) loco regional tumors are staged as L1 or L2. Children with metastatic 
tumors are defined as stage M except for children below 18 months of age with metastatic 
spread to liver, skin and bone marrow that are defined as MS (Monclair et al., 2009). The 
stage of the disease is combined with other prognostic factors into a classification system that 
stratifies patients into pretreatment subgroups. The International Neuroblastoma Risk Group 
classification system defines neuroblastoma risk groups as very low, low, intermediate, and 
high based on histology, age at diagnosis and genetic aberrations such as MYCN status, 11q-
deletion and DNA ploidy (Cohn et al., 2009). 
Treatment of neuroblastoma is funded on which risk group the patients are stratified into. The 
treatment differ widely between low-risk and high-risk groups. Treatment of high-risk 
patients involves intense induction chemotherapy regimen including cisplatin, vincristine, 
carboplatin, etoposide and cyclophosphamide known as COJEC (Ladenstein et al., 2017; 
Pearson et al., 2008). The induction chemotherapy is then followed by surgery and 
myeloablative chemotherapy combined with reinfusion of hematopoietic stem cells and later 
local radiotherapy. Maintenance treatment consists of differentiating therapy with retinoic 
acid in combination with immunotherapy, including combinations of monoclonal antibodies 
targeting disialoganglioside 2 (GD2) and granulocyte macrophage colony stimulating factor 
(GM-CSF) and interleukin (IL)-2 (Ladenstein et al., 2010; Matthay et al., 2016; Park et al., 
2014). Children in the intermediate-risk group receive a milder chemotherapy regimen 
followed by surgical resection of the remaining tumor. Treatment stratification in the low-risk 
groups aims to deliver minimum therapy, where some children can be cured solely by local 
surgery while no treatment may be needed for the metastatic neuroblastomas that 
spontaneously regress (Matthay et al., 2016). Patients with low- and intermediate-risk 
neuroblastoma have an overall survival rate above 90% while only 40-50% of the high-risk 
children will be long term survivors (Park et al., 2014). 
 
1.3 THE TUMOR MICROENVIRONMENT 
Solid tumors are not only composed of malignant cells. Solid tumors are heterogenic and 
composed of a variety of cellular components including cancer cells, endothelial cells, the 
non-cellular extracellular matrix (ECM), various immune cells and cancer-associated 
fibroblasts (CAFs) (Figure 4). The complex interplay between these components contributes 
to cancer initiation and promotes growth and metastasis. The “seed” and the “soil” hypothesis 
by Padget in 1898 was the first to describe the importance of the tumor microenvironment 
where the cancer cell (the seed) required a specific microenvironment (the soil) to establish 
and grow (Paget, 1989). As the tumor grow, cells in the microenvironment co-evolve and 
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modulates the cancer milieu into a state that actively contributes to cancer progression 
(Bissell and Radisky, 2001; Hanahan and Weinberg, 2011). This capability to change the 
surroundings is important for tumor cells to acquire some of the hallmarks of cancer. Thus 
targeting of the tumor microenvironment to destroy cancer cells in their local milieu has 
become an important tool in the overall cancer treatment (Martin et al., 2016). Different ways 
of targeting the stromal compartment within the microenvironment is frequently revealed and 
studies including anti-angiogenic drugs, immunotherapies that boost the immune responses 
against cancer, targeting-cancer associated fibroblast (CAF) markers and remodeling of the 
ECM have been initiated (Bonnans et al., 2014; Sharma et al., 2011; Sounni and Noel, 2013).  
 
 
1.3.1 Cancer associated fibroblasts 
Fibroblast is one of the most abundant cell type detected within the tumor microenvironment. 
Fibroblasts found in close proximity to cancer cells within the tumor microenvironment have 
been termed cancer-associated fibroblasts (CAFs). Fibroblasts are cells of the connective 
tissue that mediates wound healing by synthesizing the ECM, recruiting inflammatory cells 
and producing cytokines and chemokines. Cancer has been described as a wound that never 
heals implying that the processes associated with wound healing are comparable to those 
involved in the development and growth of tumor stroma (Dvorak, 1986). During wound 
healing fibroblasts are recruited and activated to repair damaged tissue, and when the healing 
process is completed activated fibroblasts decrease by undergoing apoptosis or by reverting 
to a quiescent state (Ohlund et al., 2014). In contrast, CAFs stays continuously activated.  
Activated fibroblast within the tumor microenvironment display an altered phenotype and are 
characterized by expression of α-smooth-muscle actin (αSMA), fibroblast activating protein 
(FAP), Fibroblast specific protein (FSP-1), platelet-derived growth factor receptor α and β 
(PDGFR α and PDGFR β) and vimentin (Shiga et al., 2015). However, the heterogeneity in 
expression of these markers indicates that CAFs are polarized into distinct subpopulations 
Figure 4. The tumor microenvironment. 
Tumor formation involves the co-evolution of 
neoplastic cells together with extracellular 
matrix and vascular endothelial, stromal and 
immune cells. Reprinted by permission from 
Macmillan Publishers Ltd: Nature, advance 
online publication, 19 September 2013 
(doi:10.1038/sj.nature12626)  
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depending on their origin and the local tumor environment (Augsten, 2014; Sugimoto et al., 
2006). 
The origin of CAFs is still not totally clear. In general, CAFs have been considered to 
originate from local fibroblast stimulated by factors released by tumor cells. However CAFs 
have been reported to derive from several different cell types including mesenchymal stem 
cells, hematopoietic stem cells and from epithelial cells via epithelial to mesenchymal 
transition (Oumlhlund et al., 2014). The heterogeneity of CAFs and their different functions 
has yet to be explored. 
1.3.2 CAFs in tumorigenesis 
Accumulating evidence indicates that CAFs play a prominent role in cancer pathogenesis. 
The tumor-promoting mechanisms of CAFs involve the release of growth factors and 
cytokines, which promote tumor cell growth, angiogenesis, migration and immune 
modulation (Hanahan and Weinberg, 2011; Kalluri, 2016). Generally, CAFs are thought to 
contribute to an immunosuppressive tumor microenvironment. By releasing IL-4 and IL-8 
CAFs induce differentiation of monocytes into pro-tumoral M2 macrophages that produce 
IL-10 and transforming growth factor β (TGF- β) (Kalluri, 2016; Takahashi et al., 2017). 
FAP positive CAFs have been demonstrated to oppose the Th1 response conducted via tumor 
necrosis factor α (TNF α) and interferon γ (INFγ) and depletion of FAP positive cells 
restored immune destruction of tumor cells (Kraman et al., 2010). Targeting of FAP positive 
cells in immune-competent cancer mouse models induced tumor cell destruction by 
recruitment of cytotoxic T lymphocyte (CTLs) (Wen et al., 2010). However, depletion of 
αSMA expressing cells induced immunosuppression and reduced survival in a murine 
pancreas model (Ozdemir et al., 2015). Taking CAF polarization phenotype into 
consideration may reveal a more accurate view of how they influence tumor immunity.  
Activated fibroblast within tumors produce a plethora of factors that directly or indirectly 
promotes proliferation, angiogenesis, drug resistance and metastasis. Fibroblast-derived 
growth factors include TGFβ, fibroblast growth factor and hepatocyte growth factor, and the 
chemokine CXCL12. These factors stimulates cancer growth, cellular transformation and 
induce migratory properties of cancer cells (Bhowmick et al., 2004). The role of CAFs in 
angiogenesis by the release of vascular endothelial growth factor (VGEF) has been described 
in several studies (Fukumura et al., 1998; Pietras and Ostman, 2010). Platelet derived growth 
factor (PDGF) indirectly promotes angiogenesis by recruiting VEGF producing CAFs 
(Ferrara, 2010). Furthermore, prostaglandin E2 (PGE2) produced by CAFs has been found to 
induce VGEF expression (Amano et al., 2003). In recent years CAFs has emerged as players 
in the development of resistance to anti-cancer therapies (Li et al., 2015; Paraiso and Smalley, 
2013). CAFs can, apart from affecting the sensitivity of cancer cells to chemo- and 
radiotherapy by the release of soluble factors, modulate the ECM and thereby build up a 
physical barrier that inhibit drug delivery. Enzymatic targeting of CAF-produced ECM in 
combination with chemotherapy resulted in increased overall survival (Provenzano et al., 
2012).  
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CAFs represents an attractive therapeutic target since they, in contrast to cancer cells, are 
genetically stable with less risk of developing drug resistance. However the heterogeneity 
seen in CAFs and the increasing evidence that CAFs can work as both positive and negative 
regulators of cancer growth makes targeting of CAFs more complex. It has been proposed 
that there are several subset of polarized CAFs, much like the M1 and M2 polarized 
macrophages, with either tumor-suppressive effects or tumor promoting effects (Augsten, 
2014). Thus a deeper understanding and characterization of CAFs is needed for successful 
specific targeting. 
1.3.3 Cancer related inflammation 
The link between cancer and inflammation was fist proposed in the19th century by Rudolf 
Virchow upon the observations that tumors frequently develop at sites of chronic 
inflammation and the presence of inflammatory cells within the tumors(Balkwill and 
Mantovani, 2001). Chronic inflammation affects many tumor-promoting aspects in the 
microenvironment(Coussens and Werb, 2002). It promotes tumor growth and survival by 
supplying growth and angiogenic factors. It also subvert host immunity and induce invasion 
and therapy resistance (Mantovani et al., 2008). In some tumors infections or inflammatory 
conditions precede the development of cancer. This is referred to as the extrinsic pathway in 
cancer inducing inflammation. In other malignancies the tumor-promoting inflammatory 
microenvironment is induced by oncogenic activation in which there is no underlying 
inflammatory conditions. This type of cancer related inflammation where transformed cells 
generates an inflammatory microenvironment by producing inflammatory mediators is called 
the intrinsic pathway (Mantovani and Pierotti, 2008). Activation of oncogenes results in 
constitutive production of inflammatory factors and malignant cells often overexpress pro-
inflammatory mediators including chemokines, eicosanoids, cytokines, and proteases 
(Candido and Hagemann, 2013).  
1.3.4 Immune cells in the tumor microenvironment 
Various types of immune cells are frequently present within the tumor microenvironment. 
Cells of the innate immunity include macrophages, dendritic cells, myeloid-derived 
suppressor cells, neutrophils, mast cells and natural killer cells. Tumors also contain T and B-
lymphocytes and cells of the adaptive immune system. Immune cells can affect malignant 
cells via production of growth factors, chemokines, cytokines, prostaglandins and reactive 
nitrogen and oxygen species. Frequently found immune cells within the tumor 
microenvironment includes T cells and macrophages (Grivennikov et al., 2010).  Naive T 
cells are primed by antigen presenting cells (APC). Upon stimulation, T cells are activated 
and produced in large numbers. Activated T cells migrate to the site of inflammation to 
eliminate harmful agents. T cells are divided into two major groups: the CD8+ cytotoxic T 
cells (CTL) and the CD4+ T helper cells. The CTLs induce apoptosis of targeted harmful 
cells. Helper T cells have no cytotoxic activity and their main function is to produce 
cytokines that induce immune responses by other cells. Based on the cytokines they release T 
helper cells are divided into Th1, Th2 and regulatory T cells (T reg). Cytokines released by 
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Th1 cells includes IL-2, INFγ and TNFα and tends to induce pro-inflammatory responses and 
regulates the development and persistence of CTLs. Th2-type cytokines include IL-4 and IL-
13, associated with humoral response regulation, and IL-10 and TGF-β, which regulate anti-
inflammatory responses (Knutson and Disis, 2005). Unbalanced ratio of Th1 and Th2 
responses are linked to a variety of inflammatory diseases including cancer (Grivennikov et 
al., 2010). Th2 polarized immune responses are known to promote tumor progression while 
Th1 responses are associated with CTL–mediated cancer cell destruction favoring tumor 
regression (Johansson et al., 2008). T regs are immunosuppressive cells that can down 
regulate T cell-mediated immunity by releasing IL-10 and TGF-β. T regs are frequently up 
regulated in cancer (Vignali et al., 2008). 
Macrophages and dendritic cells (DC) are derived from blood monocytes. When recruited 
into peripheral tissues, monocytes differentiate to dendritic cell and macrophages and local 
microenvironmental mediators determine their phenotype (Solinas et al., 2009). Based on 
their function, macrophages are divided broadly into two categories: classically activated type 
1 macrophages (M1) and alternative activated type 2 macrophages (M2). The names M1 and 
M2 were taken because they promote Th1 and Th2 responses, respectively. Classically 
activated M1 macrophages are driven by the Th1 cytokine IFNγ or in concert with 
lipopolysaccharide (LPS) (Martinez and Gordon, 2014; Sica and Mantovani, 2012). M1-
macrophages are characterized by high expression of pro-inflammatory cytokines resulting in 
polarized type 1 immune responses and natural killer cell (NK-cell) activation (Allavena et 
al., 2008; Martinez and Gordon, 2014). Classically activated macrophages have high capacity 
to present tumor-specific antigens for propagation and anti-tumor functions of T cells. M1 
macrophages phagocytize and kill target cells (Allavena et al., 2008). In contrast, M2 
macrophages dampen immune responses by inducing Th2 polarization and are involved in 
tissue remodeling and wound healing. M2 macrophages express high levels of IL-10, TGF-β, 
VGEF and matrix metalloproteinases (Chanmee et al., 2014; Heusinkveld and van der Burg, 
2011). Various factors such as IL-4, IL-13, PGE2, and TGF-β have the potential to promote 
M2 macrophage polarization (Chanmee et al., 2014; Gordon and Martinez, 2010).  
DCs are the main APC population inducing T-cell-mediated immunity. DCs transport tumor 
antigens to lymph nodes to activate tumor-specific T cell responses. However, impaired 
maturation and development of DCs by factors within the tumor microenvironment results is 
dysfunctional antitumor immune responses by DCs. i.e. impaired antigen-presenting abilities 
(Gardner and Ruffell, 2016; Zong et al., 2016). In addition, a reduced number of DC has been 
seen in several types of solid tumors.  
 
1.4 PROSTANOIDS 
Prostanoids are members of the eicosanoids family that represents oxidized products derived 
from twenty-carbon fatty acids. Prostanoids are a group of lipid mediators that are derived 
from arachidonic acid (AA) via the cyclooxygenase (COX) enzymatic pathway. Prostanoids 
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includes prostaglandins and thromboxane. Prostaglandins were first described in the 1930s, 
found in semen, and the prostate gland was thought to be the source. But it was first in the 
1960s that prostaglandins were isolated and characterized (Bergstroem and Samuelsson, 
1965; Samuelsson, 2012). In 1982 the Professors Bengt Samuelsson, Sune Bergström and 
John Vane was awarded with the Nobel Prize for their discoveries in this field. Prostanoids 
are potent biological regulators and play important roles in normal physiology and disease 
regulating immune functions, cardiovascular homeostasis, oncogenesis and gastrointestinal 
integrity (Narumiya et al., 1999; Wang et al., 2007). 
1.4.1 Prostanoid biosynthesis 
The prostanoid family includes prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α), 
prostaglandin D2 (PGD2), prostacyclin (PGI2) and thromboxane (TXA2). Prostanoids are 
formed from the precursor fatty acid AA that is located in cellular membranes and activated 
phospholipase A2 (PLA2) catalyzes its release. Free AA is then converted to the reactive 
intermediate prostaglandin H2 (PGH2) by the cyclooxygenases. There are two isoforms of 
cyclooxygenases; COX-1 and COX-2. COX-1 is expressed constitutively by most cells and 
responsible for maintaining the homeostasis of prostanoids in tissues. COX-2 on the contrary 
is induced upon inflammatory and oncogenic stimuli including cytokines and growth factors 
and is absent in most tissues under normal conditions (Wang and DuBois, 2006; Wang and 
Dubois, 2010; Wang et al., 2007). PGH2 is further catalyzed into the different prostanoids by 
their specific synthases. The prostanoids mediate their actions in an autocrine or paracrine 
manner via specific G-protein coupled receptors (GPCR) (Figure 5).  
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Figure 5. Schematic overview of the COX pathway and points of inhibition. Arachidonic acid is converted 
by cyclooxygenases (COX) to a reactive intermediate PGH2. Terminal synthases further convert PGH2 into 
prostaglandins and thromboxane. Reprinted by permission from Elsevier: Prostaglandins & Other Lipid 
Mediators, 2 june 2015 (10.1016/j.prostaglandins.2015.06.002) (Larsson and Jakobsson., 2015) 
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1.4.2 Specific prostaglandin E2 synthases 
PGE2 is the most abundant prostanoid and is involved in essential homeostatic processes, e.g. 
renal functions, smooth muscle contraction, regulation of blood pressure and gastrointestinal 
mucosal protection (Murakami and Kudo, 2004). However, PGE2 is produced in several 
pathological conditions including inflammation, fever, arthritis, tissue injury and a varietyof 
cancers. There are three known PGE2 synthases. Two are membrane associated including 
microsomal prostaglandin E synthase 1 and 2 (mPGES-1, mPGES-2) and one is found in the 
cytosol and named cytosolic prostaglandin E synthase (cPGES).  
PGE2 is predominantly synthesized by mPGES-1. mPGES-1 belongs to the Membrane-
Associated proteins in Eicosanoid and Glutathione metabolism (MAPEG) family and is 
expressed constitutively in spleen, lung, genital accessory organs and in the kidney 
(Jakobsson et al., 1999). In other tissues, mPGES-1 expression is low or absent under normal 
conditions. Expression of mPGES-1 is, like COX-2, highly inducible upon inflammatory 
stimuli including IL-1β, LPS and TNFα (Jakobsson et al., 1999; Larsson and Jakobsson, 
2015; Uracz et al., 2002; Xiao et al., 2012). This induction suggests that mPGES-1 is crucial 
for PGE2 production during inflammation. 
Functionally, mPGES-1 is capable of producing PGE2 via COX-1 and COX-2 derived 
PGH2 but mPGES-1 is to some degree preferentially linked with COX-2 and in many 
conditions concomitantly induced with COX-2(Murakami et al., 2000). Compared to the 
other PGE2 synthases, the catalytic efficiency of mPGES-1 is much higher and mPGES-1 is 
the only PGE2 synthase that is induced by inflammatory stimuli (Hara et al., 2010; Jakobsson 
et al., 1999). The two other PGE2 synthases is constitutively expressed and is shown to 
convert COX-1, but not COX-2 derived PGH2 into PGE2, indicating their involvement of 
maintaining basic levels of PGE2 (Tanioka et al., 2000). The importance of cPGES and 
mPGES-2 in vivo is not fully understood since cPGES deficient mice were perinatal lethal 
and mPGES-2 deficient mice showed no specific phenotype (Hara et al., 2010).  
PGE2 is relatively stable when synthesized in in vitro conditions. However, in vivo PGE2 is 
rapidly metabolized into an inactive form, 15-keto-PGE2 by the enzyme 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) (Tai et al., 2002). 
1.4.3 Prostaglandin E2 receptors and downstream signaling 
PGE2 acts in an autocrine or paracrine manner via four different G-protein coupled receptors 
named EP1, EP2, EP3 and EP4. Binding of PGE2 to its receptors results in the activation of 
several signal transduction pathways. Like all GPCR, EP receptors have seven trans 
membrane segments and each receptor is coupled to different Gα subunits. The downstream 
signaling pathways differ between the EP receptors depending on what family of alpha-
subunit the receptor stimulates. EP1 is a Gαq coupled GPCR. Stimulation of this receptor 
results in activation of phospholipase C resulting in intracellular calcium release from the 
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endoplasmic reticulum and activation of protein kinase C. Protein kinase C triggering results 
in activation of the MAPK pathway promoting cell growth and activation of nuclear factor-
kappa beta (NF-κβ), a transcription factor that control expression of genes responsible for 
both innate and the adaptive immune responses (Breyer et al., 2001; Dorsam and Gutkind, 
2007; Hanahan and Weinberg, 2000). Binding of PGE2 to EP2 or EP4 induces an increase in 
the levels of cyclic AMP (cAMP) due to activation of adenylatecyclase by the Gαs protein. 
cAMP stimulates protein kinase A activation that activates the PI3K-Akt pathway and the 
transcription factor cAMP–responsive element binding protein (CREB) promoting survival 
and growth (Dorsam and Gutkind, 2007; O'Callaghan and Houston, 2015). EP3 binding 
stimulates the Gαi subunit that inhibits adenylatecyclase and decreases the levels of cAMP 
(Breyer et al., 2001).  
1.4.4 The Prostaglandin E2 pathway in cancer 
Chronic inflammation is associated with high risk of cancer development and the link 
between cancer and inflammation has been known for more than a century.  
Approximately 15 % of malignancies are thought to be a consequence of chronic 
inflammation (Balkwill and Mantovani, 2001). The discovery that regular use of non-
steroidal anti-inflammatory drugs (NSAIDs) that inhibits COX-1, COX-2 or both decreased 
the development of malignancies and reduced tumor growth further supported the link 
between cancer and inflammation (Harris, 2009; Thun et al., 1991; Wang and DuBois, 2006) 
PGE2 is a key mediator in wound healing, inflammation and cancer. During tissue injury 
PGE2 is produced to attract the body’s immune cells and stimulate pathways important for 
wound healing. During normal conditions the PGE2 levels are then decreased following 
resolution of inflammation. However, cancer is referred to as “a wound that never heals” and 
levels of PGE2 never decline due to continuous production in the tumors. 
PGE2 is the most abundant prostanoid found in malignancies and PGE2 plays an essential role 
in tumor progression and has been linked to all the hallmarks of cancer (Greenhough et al., 
2009; Wang and Dubois, 2010). PGE2 signaling via the MAPK/ERK and GSK3β-β-catenin 
signaling pathways induce proliferation, and activation of the PI3K-Akt pathway promotes 
survival (Castellone et al., 2005; Wang et al., 2005). Contribution to cancer invasiveness and 
angiogenesis by PGE2 is mediated via transactivation of the epidermal growth factor receptor 
(EGFR) and induction of VEGF expression respectively (Buchanan et al., 2003; Fukuda et 
al., 2003). Recently PGE2 was reported to induce chemo-resistance by stimulating tumor 
repopulation following treatment (Kurtova et al., 2015). In addition, PGE2 is a key mediator 
in cancer related inflammation and mediates suppression of anti-tumor immunity (Kalinski, 
2012; Nakanishi and Rosenberg, 2013) 
Dysregulation of COX-2 and mPGES-1 expression resulting in higher levels of PGE2 have 
been reported in a variety of solid cancers. Upregulation of COX-2 expression was first 
reported in colorectal cancers (Eberhart et al., 1994). Since then elevated COX-2 expression 
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has been linked to advanced stage disease in several malignancies including breast cancer 
(Boland et al., 2004; Fornetti et al., 2014; Singh et al., 2007), prostate cancer (Khor et al., 
2007; Richardsen et al., 2010), lung cancer (Khuri et al., 2001) and bladder cancer (Wadhwa 
et al., 2005). Elevated COX-2 expression has also been associated with poor prognosis in the 
childhood cancers neuroblastoma (Johnsen et al., 2004) and medulloblastoma (Baryawno et 
al., 2008). High expression of mPGES-1 has been reported as a predictor of worse outcome in 
colon cancer (Sasaki et al., 2012; Yoshimatsu et al., 2001), prostate cancer (Hanaka et al., 
2009), pancreatic cancer (Hasan et al., 2008), stomach cancer (Gudis et al., 2007), head and 
neck squamous cell carcinoma (Camacho et al., 2008), lung cancer (Hanaka et al., 2009) and 
in the pediatric tumor medulloblastoma (Baryawno et al., 2008). Steady state levels of 
PGE2 in the body depend on the relative rates of PGE2 biosynthesis and the PGE2 degrading 
enzyme 15-PGDH. 15-PGDH converts PGE2 into the inactive form 15-keto PGE2. Genetic 
loss of 15-PGDH leads to increased levels of PGE2 and is believed to function as a tumor 
suppressor (Tai, 2011). Downregulation of 15-PGDH contributes to progression of pancreatic 
cancer (Pham et al., 2010), lung cancer (Hughes et al., 2008), colorectal cancer (Backlund et 
al., 2005; Yan et al., 2004) and breast cancer (Wolf et al., 2006). Taken together, the PGE2 
pathway contains several important cancer therapeutic targets relevant for a vide variety of 
malignancies. 
1.4.5 Prostaglandin E2 in tumor promoting inflammation 
Inflammation has emerged as a major cancer promoting factor and is now considered as one 
of the enabling hallmarks of cancer (Hanahan and Weinberg, 2011). Tumor promoting 
inflammation involves the ability of the tumor to evade host anti-tumor immunity. It is well 
known that interactions between malignant cells and stromal cells in the tumor 
microenvironment contribute and support cancer progression. Tumor cells can secrete 
chemokines, cytokines, and inflammatory eicosanoids that reprogram and recruit 
inflammatory cells to induce an immunosuppressive tumor microenvironment. Prostaglandins 
are key immunomodulators involved in the crosstalk of cancer cells and stromal cells in the 
tumor microenvironment. Generally, PGE2 is recognized as mediator in acute inflammation 
were it together with other prostanoids induce vasodilation enabling recruitment of 
inflammatory cells to the injured tissue. However, PGE2 also suppress mediators of acute 
inflammation leading to an immunosuppressive state and chronic inflammation. Thus, PGE2 
exerts both pro-inflammatory and immunosuppressive properties. In the context of cancer, 
the anti-inflammatory properties of PGE2 promoting cancer immune evasion are considered 
to be of most importance (Figure 6).  
Cancer immune evasion involves a shift from type-1 immunity to type-2 immune responses, 
impaired antigen-presenting cell recruitment and function, diminished cytotoxic activity of 
CTLs and NKs, and enhancement of immunosuppressive cells such as T regs and myeloid-
derived suppressor cells. By downregulating Th1 cytokines (IFNγ, TNFα and IL-2) and 
upregulation of Th2 cytokines (IL-10, IL-4, and IL-6) PGE2 helps to shift the balance away 
from the anti-tumor Th1 response towards immunosuppressive Th2 response in the 
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microenvironment (Harris et al., 2002; Snijdewint et al., 1993; Wang and Dubois, 2010)This 
shift results in decreased activation of CD8+ cytotoxic T cells allowing tumor cells to escape 
immune surveillance. PGE2 is also known to regulate the activity of different innate immune 
cells. 
Mononuclear phagocytes including monocytes, macrophages and dendritic cells (DCs) are 
frequently found within tumors. Under normal conditions mononuclear phagocytes are 
involved in tissue homeostasis and upon injury and infection, they clear harmful agents 
directly or by priming adaptive immunity and are also involved in tissue restoration (Gordon 
and Taylor, 2005). Together these cells have three main functions, antigen presentation, 
phagocytosis and cytokine production. In most solid tumors, mononuclear phagocytes are 
educated by the tumor microenvironment to support tumor growth and suppress anti-tumor 
immunity (Mantovani et al., 2008). PGE2 seems to play a prominent role in this education. In 
a recent study, genetic deletion of COX in models of melanoma, breast and colorectal cancer 
induce a shift toward anti-cancer immunity (Zelenay et al., 2015). PGE2 has also been shown 
to induce differentiation of monocytes into M2 macrophages and to induce an M1 to M2 shift 
in solid tumors (Heusinkveld and van der Burg, 2011; Zelenay et al., 2015).  
Furthermore PGE2 induce immune tolerance by altering the differentiation and maturation of 
DCs and by modulating their secretion of cytokines (Sombroek et al., 2002; Wang and 
DuBois, 2013). Diffrentiation of DC in the presence of PGE2 develops a phenotype that 
reduces CTL and NK cell mediated immunity while promoting Th2 responses (Kalinski et 
al., 1999). For example, PGE2 induces production of IL-10, a known inhibitor of DC 
maturation and shifts the balance from a Th1 to a Th2 response by reducing the IL-12 
production (De Smedt et al., 1997; Kalinski et al., 1997; Wang and DuBois, 2013). 
Furthermore, PGE2 induce T cell tolerance by up regulating CD25 and Indoleamine 2,3-
dioxygenase (IDO) (Kalinski, 2012; Trabanelli et al., 2015). PGE2 has been shown to 
promote development, recruitment and directly enhance the activity of suppressive immune 
cells such as myeloid-derived suppressor cells (Obermajer et al., 2012; Sinha et al., 2007) and 
regulatory T cells (Baratelli et al., 2005; Mahic et al., 2006).  
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1.5 INHIBITION OF PROSTAGLANDIN E2 SYNTHESIS IN CANCER 
 
1.5.1 Nonsteroidal anti-inflammatory drugs 
NSAIDs relive acute pain, fever and inflammation and are some of the worlds most widely 
used drugs. Beside their analgesic and anti-inflammatory effects, NSAIDs have been shown 
to be potent chemopreventive agents for cancer. There is abundant preclinical and clinical 
evidence of the benefit of regular use of NSAID in cancer prevention (Harris, 2009; Thun et 
al., 1991). NSAIDs target COX-1 and -2 thus inhibiting the first step in prostanoid synthesis. 
There are several types of NSAIDs. The traditional types of NSAIDs are non-selective and 
work as dual inhibitors of both COX-1 and COX-2 whereas some selectively target COX-1 
or COX-2. There are several severe side effects associated with prolonged use of non-
selective NSAIDs including gastrointestinal ulcers and bleeding. These side effects were 
thought to be caused by the disruption of the housekeeping functions of COX-1 derived 
Figure 6. PGE2 provides coordinated regulation of tumor immunosuppression. Pro-inflammatory 
prostaglandin E2 (PGE2) produced by tumor epithelial cells and/or their surrounding stromal cells induces 
immunosuppression through several ways, including: down regulating anti-tumor T helper 1 (Th 1) 
cytokines and upregulating immunosuppressive Th 2 cytokines; inhibiting CD8+ T cell proliferation and 
activity, suppressing the anti-tumor activity of natural killer cells and stimulating the expression of 
regulatory T cells (Treg) and myoilid-derived suppressor cells (MDSCs); and inhibiting CD8+ T cell anti-
tumor functions by impairing the ability of tumor cells to directly present tumor antigen, inhibiting 
dendritic cell differentiation and switching the function of dendritic cells from induction of immunity to T 
cell tolerance. The yellow CD8+ T cells have anti-tumor activity and the CD8+ T cell does not have anti-
tumor activity. The purple dendritic cells have the ability to present tumor antigens from tumor cells with 
major histocompability complex (MHC) class I molecules to activate naive CD8+ T cells. The orange 
dendritic cells do not have the ability to activate CD8+ T cells (T-cell tolerance). Reprinted by permission 
from Macmillan Publishers Ltd: Nature Reviews Cancer, advance online publication, 10 March 2010 (doi: 
10.1038/nrc2809) (Wang et al., 2010) 
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prostanoids, important for normal cellular functions in the gastrointestinal tract (Fries, 1999; 
Gabriel et al., 1991). 
To overcome this problem, selective COX-2 inhibitors (Coxibs) was developed, e.g. 
celecoxib and rofecoxib. Although lower gastrointestinal toxicity was seen, the clinical trials 
revealed an unforeseen adverse side effect with increased risk for cardio-vascular events with 
the use of Coxibs (Bresalier et al., 2005; Solomon et al., 2005). The cause of cardio-vascular 
side effects by Coxibs is thought to be due to the resulting imbalance of PGI2 and TXA2 
important for vascular homeostasis. PGI2 and TXA2 have opposing effects where PGI2 causes 
vasodilation and inhibits platelet aggregation and TXA2 promotes vasoconstriction and 
platelet aggregation. COX-2 selective NSAIDs inhibits PGI2 production but allows TXA2 
synthesis that is mainly regulated by COX-1 in platelets resulting in thrombosis and 
cardiovascular events (Funk and FitzGerald, 2007). Due to the severe side effects, several 
Coxibs have been taken of the market and the use of COX-2 inhibitors has been hampered.  
 
1.5.2 mPGES-1 inhibition 
To overcome the adverse side effects but still recapitulate the cancer chemopreventive effects 
of NSAIDs, selective mPGES-1 inhibitors have been suggested as an alternative (Samuelsson 
et al., 2007). Selective inhibition of mPGES-1 and its anti-inflammatory effects have 
successfully been demonstrated in models of acute and chronic inflammation (Guerrero et al., 
2009; Leclerc et al., 2013a; Leclerc et al., 2013b; Mbalaviele et al., 2010). Furthermore, 
genetic deletion of mPGES-1 in a mouse model of thrombogenesis reduced PGE2, increased 
PGI2 and, in contrast to COX-2 inhibition, did not increase thrombosis and vascular pressure 
(Cheng et al., 2006). The same was seen by pharmacologic inhibition of mPGES-1 which 
increased vasorelaxation in vitro by increasing PGI2 synthesis (Ozen et al., 2017). This 
indicates that mPGES-1 inhibition retains anti-inflammatory properties through PGE2 
reduction while avoiding the severe cardiovascular side effects of Coxibs. 
The development and screening of drugs with mPGES-1 inhibitory activity have manly been 
carried out in cell free conditions using mPGES-1 enzyme of human origin (Koeberle and 
Werz, 2015). Due to this, several mPGES-1 inhibitors failed to inhibit murine mPGES-1 
activity and assessment of inhibitor efficacy in vivo and pre clinical studies have been 
hampered (Korotkova and Jakobsson, 2014). Investigation of this interspecies difference 
revealed three non conserved amino acids close to the active site of mPGES-1 enzyme 
responsible for the difference among between human and rodent enzymes(Pawelzik et al., 
2010). Recently two compounds have been characterised that acts as dual inhibitors of human 
and murine mPGES-1. These compounds, named compound II (CII) and compound III 
(CIII), were shown to reduce PGE2 levels in cell-based assays as well as in murine models of 
inflammation (Leclerc et al., 2013a; Leclerc et al., 2013b). Furthermore, in contrast to genetic 
deletion of mPGES-1 that revealed a shunting of PGH2 towards thromboxane production, 
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pharmacological inhibition of mPGES-1 with compound III showed no evident shunting in 
the investigated cells (Leclerc et al., 2013a).  
The anti cancer effect of mPGES-1 targeting has been reported in genetically knockout 
models of colon cancer (Nakanishi et al., 2008), breast cancer (Howe et al., 2013) and in lung 
cancer (Takahashi et al., 2014). Xenograft studies with stable mPGES-1 knockdown in lung 
and prostate cancer cell lines also showed reduced tumor growth rate (Hanaka et al., 2009). In 
vivo studies of pharmacological inhibition of mPGES-1 in xenograft models reduced growth 
and angiogenesis of squamous carcinoma tumors (Finetti et al., 2012). However, 
pharmacological studies of mPGES-1 inhibition in preclinical tumor models have been 
limited due to the interspecies discrepancy discussed above (Larsson and Jakobsson, 2015).  
 
2 MATERIAL AND METHODS 
Detailed materials and methods are provided in paper I-IV. 
2.1 PATIENT MATERIAL 
All neuroblastoma tumor tissues used in this thesis were obtained from Astrid Lindgren 
Children’s Hospital at Karolinska University Hospital. Tissues were collected during surgery 
after a minimal of two weeks after any treatment and were snap-frozen and stored in –80°C. 
Informed consent for using tumor samples for research was obtained from parents or 
guardians according to the ethical approval from the Karolinska University Hospital Research 
Ethics Committee (approval no 2009/1369-31/1 and 03/736). Tumor and patient 
characteristics are summarized in paper I, paper II and paper III. 
2.2 HUMAN CELL LINES 
Human neuroblastoma cell lines used includes: SK-N-AS, SH-SY5Y, SK-N-SH, SK-N-FI, 
SK-N-BE (2), SK-N-DZ and IMR-32. The normal human dermal fibroblast cell line NHDF 
was used in paper IV. All cells were cultured at 37°C in a humidified 5% CO2 atmosphere in 
medium containing 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100μg/mL 
streptomycin and 100 IU/mL penicillin. 
2.3 EX VIVO AND IN VITRO ANALYSIS 
2.3.1 RNA expression 
Reverse transcription-PCR was used in paper I to analyze receptor expression in 
neuroblastoma cell lines. Quantitative Real-Time PCR Analysis was preformed to detect 
relative mRNA levels in primary neuroblastoma tumor in paper II and in in vitro models of 
neuroblastoma in paper IV. Gene expression and impact on overall survival of 
neuroblastoma patients was performed using the publicly available database R2: microarray 
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analysis and visualization platform (r2.amc.nl). mRNA from 88 human neuroblastoma 
samples, included in the Versteeg-88 dataset, was analyzed in paper II. 
2.3.2 Protein detection  
Immunohistochemical analysis was used to assess protein expression patterns and levels. In 
paper I formalin-fixed and paraffin-embedded tumor tissue sections were used and in paper 
II, paper III and paper IV snap frozen samples of tumor tissue or collected spheroids were 
sectioned. To preserve tissue morphology collected fresh tissue from experimental tumors or 
spheres was embedded, without fixation, in a cryomold with Tissue-Tech O.C.T. Compound. 
Fluorescence immunocytochemistry was preformed to study protein expression and induction 
in in vitro experiments with neuroblastoma cell lines in paper I and paper IV. Cytokine 
arrays was used to analyze relative cytokine expression in supernatants from MCTS of SK-N-
AS and NHDF cultivated together with LPS and IFNγ stimulated PBMCs or non-stimulated 
PBMCs in paper IV. Western blotting was preformed to detect relative protein levels in 
neuroblastoma cell lines (paper I), primary neuroblastoma tumors (paper II) and in 
experimental tumors (paper III). 
2.3.3 Flow cytometry 
Flow cytometric analysis of single cell suspensions of experimental tumors and spleen from 
mice treated with the selective mPGES-1 inhibitor compound III (CIII) was performed in 
paper III. Tissues were dissociated mechanically and red blood cells were lysed before 
staining. All antibodies used are listed in paper III. 
2.3.4 Cell viability assays 
Cell viability of neuroblastoma cell lines in paper I was investigated using MTT-assays. The 
proportion of viable cells in MCTS, cultivated with neuroblastoma cells (SK-N-AS) and 
fibroblasts (NHDF), were quantified by measuring cellular ATP content using the CellTiter-
Glo 3D Cell Viability Assay in paper IV. 
2.3.5 Receptor activation 
In paper I, intracellular levels of calcium and cAMP in response to PGE2 treatment was 
analyzed. Intracellular mobilization of calcium in neuroblastoma cell lines was visualized and 
measured by using the fluorescent dye Fluo-4/AM in a confocal laser-scanning microscope. 
The intracellular levels of cAMP were determined by using a cAMP ELISA EIA kit.  
2.3.6 Migration assay 
To analyze the migratory effect of mPGES-1 inhibition on fibroblasts (NHDF) co-cultured 
with neuroblastoma cells (SK-N-AS) the trans-well Boyden Chamber Cell Migration Assay 
was used in paper III. 
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2.3.7 Prostanoid measurements and pharmacokinetics 
In order to study the pharmacokinetics of CIII in paper III a targeted LC-MS/MS method 
was established. The levels of CIII was analyzed in plasma, tumor tissue and spleen collected 
2h, 4h, and 6h post intra peritoneal injection. Prostanoid levels in neuroblastoma cell lines in 
paper I, in primary neuroblastoma tumors in paper II and in experimental tumors in paper 
III was determined using LC-MS/MS. To analyze levels of PGE2 production by MCTS in 
paper IV we used prostaglandin enzyme immunoassay (EIA). 
2.4 IN VIVO EXPERIMENTS 
2.4.1 Xenograft mouse models 
Athymic female NMRI nu/nu mice were kept in pathogen free condition given food and 
sterile water in ad libitum. In paper II and paper III we subcutaneously injected 
neuroblastoma cells (SK-N-AS) on the flank of 4-8 week old mice. Tumor volume and the 
weight of the mice was measured every day post cell injection. The experiments were 
approved by the regional ethics committee for animal research (approval N231/14) in 
accordance with the Animal Protection Law (SJVFS 2012:26). 
2.4.2 TH-MYCN transgenic mouse model 
The transgenic TH-MYCN mice spontaneously develop an aggressive form of 
neuroblastoma. Expression of a MYCN construct is coupled to the tyrosine hydroxylase 
promotor expressed by neuroectodermal cells during the development of the sympathetic 
nervous system (Weiss et al., 1997). All homozygous mice develop tumors within 7 weeks 
(Rasmuson et al., 2012). The animals were kept in ventilated cages with an enriched 
environment and food provided ad libitium. In paper III we randomized homozygous 
animals into treatments group at the age of 4,5 weeks when small tumor lesions are present. 
All transgenic animal experiments were approved by the regional ethics committee for animal 
research (ethical permit N26/11 and N42/14) in accordance with the Animal Protection Law 
(SFS1988:534). 
2.5 STATISTICS 
For statistical comparisons between two independent groups we used unpaired t-test or 
Mann-Whitney test when applicable. Statistical differences of several independent groups 
were analyzed by two-way ANOVA. Kaplan-Meier estimator was used for survival analysis 
and the significance was calculated using Log-rank test (Mantel-Cox). Graphs and statistics 
was prepared and analyzed in GraphPad prism.  
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3 AIMS 
The general aim of this thesis was to assess the importance of PGE2 in neuroblastoma and to 
characterize mPGES-1 as a potential novel therapeutic target in neuroblastoma. 
Specific aims: 
Paper I. To investigate PGE2 signaling in neuroblastoma cell lines. 
 
Paper II. To study the significance of mPGES-1 in primary neuroblastoma. 
 
Paper III. To investigate the effect of pharmacological mPGES-1 inhibition in pre-clinical 
neuroblastoma mouse models.  
Paper IV. To establish an in vitro preclinical model simulating the neuroblastoma 
microenvironment, enabling mPGES-1 inhibition in combination with conventional cancer 
therapies. 
 
4 RESULTS AND DISCUSSION  
4.1 PAPER I: PGE2 SIGNALING IN NEUROBLASTOMA 
Prostaglandin E2 (PGE2) is known to promote tumor related inflammation (Kalinski, 2012; 
Wang and Dubois, 2010). Selective COX-2 inhibition was shown to reduce neuroblastoma 
growth in vitro and in vivo (Johnsen et al., 2004; Ponthan et al., 2007). In this paper we 
therefore wanted to investigate the significance of PGE2 signaling in neuroblastoma.  
 
The first step to evaluate the importance of PGE2 signaling in neuroblastoma was to study the 
expression of the specific PGE2 receptors EP1, EP2, EP3 and EP4. Immunohistochemical 
staining of 28 primary neuroblastoma tumors with different clinical background showed 
expression of all receptor subtypes. Further, expression of the receptors was analyzed in a 
panel of 7 different neuroblastoma cell lines. Expression of all the receptors was determined 
at the mRNA level with RT-PCR and at the protein level with immunofluorescence. No 
evident difference in expression pattern was recognized between clinical subsets of 
neuroblastoma neither in primary tumors nor in cell lines.  
 
Next, we evaluated the ability of neuroblastoma cells to synthesize PGE2. PGE2 levels were 
measured using LC-MS/MS. SK-N-SH cells did not produce detectable levels of PGE2 
whereas PGE2 was found to be produced by the MYCN- amplified cell line SK-N-BE (2) in 
low levels under normal growth conditions. Addition of AA, a substrate for prostanoid 
synthesis, to the culturing media resulted in increased production of PGE2 in SK-N-BE (2) 
cells but not in SK-N-SH. However arachidonic acid in combination with the inflammatory 
cytokine IL-1β, a known inducer of both COX-2 and mPGES-1, did induce PGE2 production 
in both cell lines. These findings indicated that the PGE2 synthesis pathway in neuroblastoma 
cell lines is triggered upon inflammatory stimuli. 
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Previous studies have shown that COX-inhibitors impede neuroblastoma cell growth 
(Johnsen et al., 2004). This and the knowledge that neuroblastoma cells express all the EP 
receptors made us examine the direct effect of PGE2 on cell growth. Increasing 
concentrations of PGE2 was added to the culturing media of serum starved cells and cell 
viability was measured using 3 -(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) after 24, 48, 72 and 96 hours. PGE2 significantly increased neuroblastoma cell 
viability in a dose and time dependent manner. Furthermore, we could rescue neuroblastoma 
cells from celecoxib-induced cytotoxicity by adding PGE2. This shows that PGE2 has a direct 
effect on neuroblastoma cell growth and not only supports tumor growth by contributing to a 
cancer-promoting inflammatory microenvironment. An increase in cell proliferation by PGE2 
has also been demonstrated in medulloblastoma, another neural embryonic tumor (Baryawno 
et al., 2008). The proliferative effect of PGE2 on cancer cells has mainly been reported in 
cancer of epithelial origin. 
 
To confirm PGE2-induced receptor activation and to assess the mitogenic mechanism behind 
the observed increase in neuroblastoma cell viability, we analyzed intracellular downstream 
second messengers and effectors upon PGE2 activation.  
EP1 activation results in mobilization of intracellular calcium and by using fluorescent 
calcium dye Fluo-4/AM we could visualize a rapid increase in cytoplasmic calcium levels 
when adding PGE2 to neuroblastoma cells. Since EP2, EP3 and EP4 acts via adenylate 
cyclase and cAMP we treated neuroblastoma cells with PGE2 and determined the intracellular 
levels of cAMP. EP2 and EP4 signals via Gαs-protein that stimulates cAMP production 
while EP3 is linked to Gαi-protein inhibiting cAMP production. After 20 minutes of PGE2 
incubation a net response of increased cAMP was observed. A Gαs protein inhibitor could 
prevent this effect.  
 
PGE2 have been reported to induce survival, proliferation and invasion via activation of 
several mitogenic pathways in carcinomas including the Ras-Erk, GSK3β- β catenin and 
PI3K-Akt pathway (Wang and Dubois, 2010). Western blotting of PGE2 treated 
neuroblastoma cells showed a time dependent increased in phosphorylated Akt, a protein 
involved in cancer cell survival and proliferation. The PI3K-Akt pathway is the one of the 
most common and potent survival signaling cascades in cancer (Vivanco and Sawyers, 2002). 
Previous, phosphorylated Akt has been linked to decreased overall survival in neuroblastoma 
(Opel et al., 2007) and another study found Akt and mTOR to be activated in all tumors in a 
panel of 30 primary neuroblastomas while no activation was found in non-malignant adrenal 
glands (Johnsen et al., 2008). Here we show PGE2 to be an activator of Akt in neuroblastoma 
resulting in increased cell survival. 
 
EP receptor targeting has been proposed as a possible alternative to COX-inhibition. We 
wanted to evaluate this possibility and elucidate if any of the receptors are of greater 
importance for neuroblastoma growth. We treated six different neuroblastoma cell lines with 
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a panel of EP- receptor antagonists and evaluated cell viability. All the antagonists reduced 
neuroblastoma cell growth and the drugs selectively targeting EP1, EP3 and EP4 were most 
effective in reducing cell viability. This suggests that more than one receptor is important in 
neuroblastoma growth. However, it is difficult to draw conclusions of the importance of 
specific receptors since receptor affinity, drug specificity and levels of receptor expression 
should be taken into consideration. Several preclinical studies with EP receptor antagonists 
have been successful in hampering tumor growth (O'Callaghan and Houston, 2015).  
 
Comparison of EP receptor expression using public available expression arrays of 
neuroblastoma (http://r2.amc.nl, R2) shows that high expression of EP2 have the worst 
impact on overall survival of neuroblastoma patients. At the time of this study selective EP2 
antagonists was not commercially available and most research of EP2 receptor have been 
conducted in EP2-deficient mice. However, a novel selective EP2 receptor antagonist has 
shown promising results in cancer studies (af Forselles et al., 2011; Aoki and Narumiya, 
2017; Jiang and Dingledine, 2013). This enables further studies of the impact of PGE2-EP2 
signaling in neuroblastoma. Furthermore, several studies have proven an existing 
transactivation of EGF receptor via EP receptors, adding further complexity to the PGE2 
signaling pathway (Han et al., 2006; Oshima et al., 2011; Pai et al., 2002). Whether 
combinational treatment of EP antagonist with different receptor selectivity could improve 
the anti-cancer effect is yet to be elucidated. 
 
Taken together our results demonstrate that PGE2 production can be induced in 
neuroblastoma cells, and that the EP receptors are abundantly expressed and activated by 
PGE2 resulting in cancer survival signaling cascades, hence creating an autocrine or a 
paracrine survival loop for neuroblastoma (Figure 7). This suggests that selective targeting of 
PGE2 signaling and production could be an alternative therapeutic approach in neuroblastoma 
that potentially could avoid possible side effects of COX-inhibitors. 
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Figure 7. Simplified illustration of PGE2 signaling in 
neurblastoma. Neuroblastoma cells express all EP 
receptors. EP receptor activation by PGE2 results in 
downstream phosphorylation of Akt and activation of 
survival signaling cascades. 
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4.2 PAPER II: MPGES-1 IN NEUROBLASTOMA 
PGE2 is known to influence cells in the tumor by subverting host anti-tumor responses 
promoting an immunosuppressive tumor microenvironment. Although many adult cancers 
are presented with an inflammatory microenvironment, the knowledge is limited on 
importance of inflammation in childhood malignancies. In this study, we focused on the 
inflammatory COX/mPGES-1/PGE2 pathway in different clinical subsets of neuroblastoma. 
We first analyzed mRNA expression levels of mPGES-1, COX-1 and COX-2 in primary 
neuroblastoma tumors of different subtypes. The high-risk group included MYCN-amplified 
and 11q-deleted tumors. The low-risk group included tumors that had been defined as L or 
MS according to the International Neuroblastoma Risk Group staging system (INRGSS). The 
relative expression of mPGES-1 and COX-1 was found to be significantly higher in the 11q-
deleted tumors compared to the low-risk group. The increased expression of mPGES-1 seen 
in the 11q-deleted tumors was validated by mPGES-1 expression analysis using public gene 
expression platforms showing that high levels of mPGES-1 expression correlated with 
reduced overall survival in high-risk neuroblastoma. Protein expression of synthases involved 
in prostaglandin synthesis was analyzed by immunohistochemistry. Quantification of protein 
levels of mPGES-1, COX-1 and COX-2 confirmed the mRNA levels showing significantly 
higher levels of mPGES-1 in the 11q-deleted tumors. COX-1 protein expression was 
comparatively higher than COX-2 expression in the samples. However, no significant 
differences were found in COX-1 and COX-2 protein levels between the different subgroups. 
Surprisingly overall low levels of COX-2 was detected in the analyzed neuroblastoma 
samples. A previous study has described neuroblastoma with high COX-2 expression 
(Johnsen et al., 2004). Comparison of COX-2 expression in this study was done between 
malignant tissue and non-malignant adrenal glands whereas we compared differences within 
subgroups of cancerous tissues that partly could explain these discrepancies.   
Next, we evaluated the actual levels of prostaglandins in neuroblastoma tissues. 
Prostaglandins were measured with LC-MS/MS in a panel of 29 primary neuroblastoma 
tumors. Significantly higher levels of PGE2 were found in 11q-deleted tumors compared to 
both MYCN-amplified tumors and low-risk tumors. Interestingly 15-PGDH, the PGE2 
degrading enzyme was expressed at significantly lower levels in 11q-deleted tumors. The 
balance between the activity of PGE2 synthases and 15-PGDH determines the level of PGE2 
production. In 11q-deleted neuroblastomas the high expression of mPGES-1 and the low 
expression of 15-PGDH plausible causes the high levels of PGE2. Down regulation of 15-
PGDH have been described to contribute to pathological levels of PGE2 in a variety of 
malignancies and 15-PGDH has been proposed to act as a tumor suppressor (Tai, 2011). 15-
PGDH have been shown to be down regulated by epigenetic repression (Backlund et al., 
2008; Lodygin et al., 2005). It would be of interest to evaluate the transcriptional regulation 
of 15-PGDH in neuroblastoma and assess 15-PGDH as a possible therapeutic target. 
Patients with 11q-deletions are often older at disease onset and have slower disease 
progression compared to patient with MYCN-amplified tumors. A recent analysis showed that 
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children with non-MYCN amplified high-risk tumors that are older than 18 months at 
diagnosis have higher expression levels of inflammatory genes (Asgharzadeh et al., 
2012).Together with our results this suggests that high-risk 11q-deleted neuroblastoma 
tumors from older children presents a more inflammatory phenotype. 
Tumors with high expression of mPGES-1 resulting in elevated levels of PGE2 are mostly 
carcinomas, cancer with epithelial origin (Nakanishi et al., 2010). An exception is the 
embryonic tumor medulloblastoma that, like neuroblastoma originates from neural cells, also 
express high levels of mPGES-1 (Baryawno et al., 2008). However, in these tumors mPGES-
1 is predominantly expressed by neoplastic cells. Unexpectedly, immunohistochemical 
analysis of mPGES-1 protein expression in neuroblastoma tumors revealed a staining pattern 
resulting from stromal cells or infiltrating cells rather than tumor cells. To confirm this a 
double staining with antibodies against mPGES-1 and GD2, a marker for tumors of neuro 
ectodermal origin, was performed. A clear discrepancy in staining pattern was seen indicating 
that PGE2 in the tumors are produced by cells in the tumor stroma and not by the tumor cells. 
Most cells of the body can produce PGE2. However, epithelial cells, infiltrating immune cells 
and fibroblasts present the major sources of PGE2 in inflammatory responses.  
Dual labeling with mPGES-1 and the endothelial marker CD31 exhibited no co-expression. 
To further localize the cellular origin of mPGES-1 expression and to consider the level of 
PGE2 signaling and inflammation in the tumor microenvironment we analyzed immune cell 
markers together with mPGES-1. Tumors from the three different subsets were analyzed. 
Macrophages are known to express mPGES-1 (Westman et al., 2004). Abundant expression 
of both the macrophage marker CD68 and M2 polarized macrophages marker CD163 was 
evident in all tumors analyzed. However, no co-localization was found between mPGES-1 
and the macrophage markers. To evaluate the degree of macrophage infiltration and 
polarization we quantified expression of M1 and M2 markers in tumors. The staining 
revealed a shift towards an M2 polarization phenotype in the high-risk tumors compared to 
low-risk tumors. Neuroblastoma have been described to contain an immunosuppressive 
microenvironment hampering anti-tumor immunity (Pistoia et al., 2013). Our results 
correspond with the findings by Asgharzadeh and colleges revealing significantly greater 
numbers of CD163 positive cells in high-risk metastatic tumors compared to low-risk tumors 
(Asgharzadeh et al., 2012). 
Other myeloid cells, which apart from being directly regulated by PGE2 have been reported to 
actively produce PGE2 are dendritic cells and MDSCs (Fogel-Petrovic et al., 2004; Serafini, 
2010). To assess mPGES-1 expression by dendritic cells and to cover all myeloid cells 
double staining of mPGES-1 together with CD11c and CD11b was preformed. None of the 
dendritic- or myeloid- cell markers co-localized with mPGES-1. However, CD11c expressing 
dendritic cells was found exclusively in areas with mPGES-1 expressing cells. Next we 
studied lymphocyte infiltration. T-cells were present in all investigated tumors in proximity to 
mPGES-1 positive cells. Interestingly, only the tumors in the low risk group that 
spontaneously regress showed abundant presence of B-cells. 
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To assess whether the mPGES-1 expressing cells were of mesenchymal origin we preformed 
dual labeling with mPGES-1 and vimentin. The majority mPGES-1 expressing cells in 
MYCN-amplified and low risk tumors did express vimentin. However, vimentin was widely 
expressed in the tumors and not exclusively expressed by mPGES-1 positive cells. Since 
mPGES-1 did coincide with the mesenchymal marker vimentin and since fibroblasts have 
been reported to produce PGE2 we analyzed mPGES-1 expression together with a panel of 
CAF markers including αSMA, PDGFRβ, PDGFRα, FAP and FSP-1. In the tumors 
evaluated, expression of mPGES-1 was found to overlap with one or more markers of CAFs. 
Our results are in line with findings in a recent study of head and neck squamous carcinoma, 
where cancer cells induced fibroblasts to express mPGES-1 and release PGE2 (Alcolea et al., 
2014). There is accumulating evidence that fibroblasts within the tumor play an important 
role in cancer pathogenesis. CAFs have been shown to promote an immunosuppressive 
microenvironment and have even been suggested as targets for immunotherapy. One recent 
study shows that CAFs are educated by cancer cells and contributes to tumor enhancing 
inflammation via NF-κβ (Erez et al., 2010), a transcription factor implied in regulation of 
mPGES-1 expression (Bage et al., 2010; Diaz-Munoz et al., 2010). 
Finally, we evaluated the effect of PGE2 inhibition on neuroblastoma growth in a preclinical 
11q-deleted xenograft model. Tumor bearing mice were treated with the non-selective COX 
inhibitor diclofenac. This resulted in a significant reduction of tumor growth and decreased 
PGE2 levels. 
In conclusion, we show that high-risk neuroblastoma tumors present an immunosuppressive 
microenvironment and that the inflammatory COX/mPGES-1/PGE2 pathway is highly 
activated in 11q-deleted neuroblastomas. In addition, our findings suggest that cancer-
associated fibroblasts and PGE2 might play a role in the complex tumor-stroma interactions 
within the tumor microenvironment and promote neuroblastoma-related inflammation.  
4.3 PAPER III: MPGES-1 INHIBITION IN NEUROBLASTOMA 
In this study we aimed to investigate specific effects of pharmacological mPGES-1 inhibition 
in PGE2 producing CAFs using pre-clinical in vivo models of high-risk neuroblastoma. To 
mimic high-risk 11q-deleted tumors we xenografted human SK-N-AS cells with confirmed 
11q-deletion in NMRI mice. We also used the MYCN-driven transgenic TH-MYCN mouse 
model. These animals spontaneously develop an extremely aggressive form of neuroblastoma 
resembling human MYCN-amplified tumors (Rasmuson et al., 2012; Weiss et al., 1997). 
Expression of mPGES-1 in both in vivo tumor models was detected exclusively in PDGFRβ 
expressing cells, a marker for CAFs, and not in malignant cells similar to what we previously 
described in human neuroblastomas. Interestingly, STAT3, one of the major regulators of 
tumor-promoting inflammation was activated in mPGES-1 expressing cells (Yu et al., 2009).  
Since we in paper I and in paper II revealed an active PGE2 pathway in neuroblastoma we 
investigated the expression of PGE2 receptors in the two in vivo models and in corresponding 
primary human tumors. All receptors subtypes were abundantly expressed as seen in paper I. 
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EP4, however, was predominantly expressed in the stromal cells of both the 11q-deleted and 
MYCN-amplified tumors. The expression pattern of the receptors in the model tumors 
corresponded to the primary high-risk neuroblastoma subsets. This suggests that PGE2 
production and signaling is conducted in the same manner in primary human neuroblastomas 
and in the two corresponding mouse models. Taken together this underlines the relevance of 
these preclinical neuroblastoma models for pharmacological targeting of mPGES-1. 
There are phenotypic differences between the human and murine mPGES-1 enzyme. Three 
amino acids differ leading to inhibitors developed to the human enzyme inefficient towards 
murine mPGES-1 (Pawelzik et al., 2010). Recently the small molecule inhibitor Compound 
III (CIII) was characterized as a selective dual human/rodent mPGES-1 inhibitor with 
efficacy in both in vitro and in vivo murine models of inflammation but have never 
investigated as an anti-cancer agent (Leclerc et al., 2013a; Olesch et al., 2015). In order to 
study the pharmacokinetics of CIII a targeted LC-MS/MS method was established. A rapid 
uptake of CIII was revealed with the highest concentration in plasma and tumor tissues at 
around 2 h post injection. The reduction of PGE2 levels follows the concentration of CIII with 
the highest effect on PGE2 inhibition 2 h after administration. We did not detect any other 
prostanoids in the tumors and expression of mPGES-1 and COX-1 in tumor tissue were 
unchanged with CIII treatment.  
The therapeutic effect of the mPGES-1 inhibitor CIII on neuroblastoma growth was then 
assessed in the two models of high-risk neuroblastoma. Mice with xenografted 11-q deleted 
tumors were treated daily with CIII (50 mg/kg) either as a prophylactic treatment from the 
day of tumor cell injection or as a treatment of established tumors, starting at a tumor volume 
of 0.2 ml. The early initiated prophylactic treatment did not delay early tumor establishment, 
however the treatment significantly hampered the development of large macroscopic tumors 
with a volume of ≥1 ml. Treatment of established tumors, starting at 0.2 ml, significantly 
reduced tumor volume compared to the untreated control group. Clearly, the daily transient 
reduction in PGE2 levels had a distinct impact on tumor growth. Even though the 
prophylactic treatment with CIII did not delay tumor formation, the aggressive growth rate 
seen in untreated mice once tumors were established was significantly reduced. Prophylactic 
treatment with CIII and treatment of established tumors resulted in the same tumor weight at 
sacrifice. This could mean that mPGES-1 targeting at an early time point promotes a less 
malignant microenvironment hampering tumor growth. At the same time, targeting of 
mPGES-1 in an established PGE2 dependent and immunosuppressive tumor milieu might be 
sufficient to halt neuroblastoma growth.  
Next we evaluated the effect of selective mPGES-1 inhibition on tumor growth in fully 
immune competent TH-MYCN transgenic mice. Homozygous TH-MYCN transgenic mice 
were treated daily with CIII (50mg/kg) from the age of 4.5 week, an age when only small 
tumor lesions are present (Carlson et al., 2013), until 6 weeks of age. Tumor growth was 
significantly reduced in CIII treated mice. 
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To compare effect of selective mPGES-1 inhibition with non-selective COX inhibition on 
neuroblastoma growth we treated homozygous TH-MYCN mice with diclofenac in the 
drinking water (10 mg/L) for 14 days. The tumor weight reduction was comparable with 
effect seen by CIII treatment. COX inhibition is widely studied and has great potential 
foremost as preventive treatment in adult cancer (Wang and Dubois, 2010).PGE2 inhibition 
envisioned great promise in combination with conventional cancer treatments such as 
radiation therapy (Brocard et al., 2015) and chemotherapy(Ponthan et al., 2007). PGE2 
inhibition also proved to reduce chemo resistance (Kurtova et al., 2015). In a recent report a 
synergistic effect of COX inhibition and PD-1 blockade in in vivo models of melanoma, 
breast and colorectal cancer was shown (Zelenay et al., 2015). However, the severe side 
effects associated with COX inhibitors on both the gastrointestinal tract and the 
cardiovascular system has limited their clinical use. The TH-MYCN model is known for its 
extremely aggressive growth and it is difficult to halt tumor progression once the tumor is 
established (Eissler et al., 2016; Rasmuson et al., 2012). We were able to suppress the tumor 
growth with a single treatment, seemingly without any toxic side effects, targeting the tumor-
stroma interaction. With pharmacological mPGES-1 inhibition we would recapitulate the 
anti-tumor benefits of COX inhibition without the side effects caused by the systemic and 
unspecific reduction of all prostanoids. 
PGE2 contributes to an immunosuppressive milieu leading to inhibition of anti-tumor 
immunity (Nakanishi and Rosenberg, 2013; Sinha et al., 2007; Wang and Dubois, 2010). 
Neuroblastoma presents an immunosuppressive microenvironment (Borriello et al., 2015; 
Pistoia et al., 2013) and high-risk neuroblastoma has been described with higher infiltration 
of alternatively activated macrophages (M2) compared with loco regional neuroblastoma 
(Asgharzadeh et al., 2012). Furthermore, the tumor microenvironment of TH-MYCN mice 
promotes a transition of macrophages towards a tumor promoting M2 phenotype during 
tumor progression (Carlson et al., 2013; Mao et al., 2016). We therefore analyzed 
macrophage polarization markers, CD86 (M1) and CD206 (M2) in tumor and spleen from 
mice treated with CIII to assess the immunomodulatory effect of mPGES-1 inhibition.  
Immunohistochemical staining revealed a decrease in tumor-promoting M2 macrophages in 
the CIII treated tumors. In addition, flow cytometry analysis showed a significant shift 
towards M1 polarization while total macrophage frequencies remained unchanged. This 
demonstrates that mPGES-1 targeting support anti-tumor immunity via macrophage 
education toward an M1 phenotype. 
Angiogenesis is a rate-limiting factor in tumor development and progression. The PGE2 
pathway is known to promote angiogenesis and COX-2 inhibition has anti-angiogenic 
properties in neuroblastoma (Jain et al., 2008; Liu et al., 2015; Ponthan et al., 2007). We 
therefore analyzed the impact of new vessel formation by mPGES-1 inhibition using 
immunohistochemistry. A significant decrease in CD31 expression, an endothelial cell 
marker, was seen in TH-MYCN tumors with CIII. This indicates that selective mPGES-1 
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inhibition can recapitulate the anti-angiogenic effect of COX-2 inhibition and that treatment 
at an early state hampers angiogenesis and thereby tumor development.  
Lately several reports demonstrate that CAFs promote an immunosuppressive tumor 
microenvironment via M2 polarization. Since PDGFRβ positive CAFs in the experimental 
tumors express mPGES-1 and the immune regulator STAT3 we analyzed the amount of 
PDGFRβ positive cells in CIII treated tumors. CIII treatment resulted in less PDGFRβ 
positive cells in the TH-MYCN tumors and in the prophylactic treated xenograft tumors. 
There was no difference in tumors from mice that received CIII after tumor establishment. 
This suggests that CIII targeting not only directly inhibits PGE2 synthesis but also, in the 
developing tumor microenvironment, indirectly reduce PGE2 and thereby alters the tumor 
malignancy.  
Finally, we investigated the impact of PGE2 signaling in tumor-promoting recruitment of 
fibroblasts in vitro. One important inducer of mPGES-1 is IL-1β (Jakobsson et al., 1999) and 
the receptor IL-1 receptor type I (IL-1RI) coincided with mPGES-1expressing PDGFRβ 
positive cells in experimental tumors. In vitro, IL-1β induced mPGES-1 expression and 
migration of human dermal fibroblasts towards neuroblastoma SK-N-AS cells in a transwell 
assay. Fibroblast migration was reduced in the presence of CIII or an EP4 antagonist, 
suggesting that PGE2 plays a role in fibroblast migration and infiltration in high-risk 
neuroblastoma. 
Taken together our results demonstrate that pharmacologic mPGES-1 inhibition alters the 
tumor microenvironment and hampers tumor progression in neuroblastoma (Figure 8).  
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Figure 8. Illustration of the role of PGE2 in neuroblastoma. CAFs residing in the tumor express 
PDGFRβ and IL-1RI. IL-1β in the tumor microenvironment stimulates mPGES-1 expression and leads to 
PGE2 production. PGE2 release from the CAFs leads to increased angiogenesis, an immunosuppressive 
microenvironment and tumor growth. By inhibiting mPGES-1 with CIII the actions of PGE2 is reversed 
and the tumor growth halted. The illustration is from paper III. 
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4.4 PAPER IV: MPGES-1 INHIBITION IN COMBINATION WITH 
CONVENTIONAL CANCER THERAPIES 
Tumorigenesis has generally been looked upon as a cell-autonomous activity where genetic 
events result in cell transformation and neoplastic growth. Today, however, the significance 
of stromal cells populating the tumor microenvironment that promote tumor growth and 
development is well established (Bissell and Radisky, 2001).  
In paper II we show that high-risk neuroblastoma presents an immunosuppressive 
microenvironment and fibroblasts within the tumors express mPGES-1. In paper III PGE2 
targeting by pharmacological inhibition of mPGES-1 resulted in a less tumor-promoting 
microenvironment and reduced neuroblastoma growth. In this study we aimed to establish a 
preclinical in vitro model simulating the neuroblastoma microenvironment. This would 
enable further understanding of the complex cellular interactions and provide us with a 
screening tool for targeting PGE2 driven tumor-stroma interaction in combination with 
conventional therapies that mainly targets transformed cancer cells. 
Evaluation of mPGES-1 expression in monocultures of fibroblasts and co-cultures of 
fibroblasts and neuroblastoma cells in monolayer cultures revealed no induced mPGES-1 
expression without IL-1β stimulation.  
Important functions of cells seen in tissues are lost when the cells are forced to grow as 
monolayers in culture. In contrast, three dimensional (3D) cultures retain many cancer tissue 
features including hypoxic gradients, cells in different metabolic and proliferative state, 
limited drug penetration and improved cell-cell contact (Pampaloni et al., 2007). In order to 
recapitulate the pathobiology described in neuroblastoma we decided to establish 
multicellular tumor spheroids (MCTS) by co-culturing fibroblasts and neuroblastoma cell 
lines in non-adherent conditions. By doing so we could retain in vivo features with a 
proliferative and hypoxic gradient. We could also detect an induced mPGES-1 expression not 
seen in 2D co-cultures underlining the importance of the in vivo characteristics seen in 3D 
models. 
In order to analyze the phenotype of fibroblasts grown together with neuroblastoma cells in 
MCST we preformed immunohistochemistry with mPGES-1 and a panel of CAF markers. 
mPGES-1 expression coincided with markers of CAFs in the MCTS in agreement with 
mPGES-1 expression in primary tumors and experimental tumors of neuroblastoma. The 
fibroblast population expressed FAP, vimentin, FSP-1, PDGFRβ and PDGFRα. However, 
the marker αSMA, a myofibroblasts marker expressed by activated fibroblast during wound 
healing was only weakly expressed. Accumulating reports describe fibroblasts within the 
tumor microenvironment as a heterogenic cell population with differently polarized 
subpopulations (Augsten, 2014; Sugimoto et al., 2006). It is generally thougt that CAFs are 
related to myofibroblasts. However, all fibroblasts within the tumors do not express αSMA 
but these cells are still thought to possess tumor promoting abilities (Erez et al., 2010). 
Interestingly, fibroblasts within MCTS expressing mPGES-1 also expressed IL-1RI similar to 
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the experimental tumors. IL-1β is one of the main inducer of mPGES-1 and cancer cells have 
been shown to activate fibroblasts to induce tumor-promoting inflammation in response to 
IL-1β stimulation (Erez et al., 2010). 
By growing tissue-derived tumor spheroids (TDTS) generated by partial enzymatic 
dissociation of tumor tissue we wanted to evaluate if we could preserve the phenotype of 
stromal cells that have been educated in an authentic microenvironment. Characterization of 
the TDTS showed a clear proliferative gradient and in resemblance to in vivo experimental 
tumors mPGES-1 coincided with PDGFRβ as described in Paper III. However, the ratio of 
fibroblasts and cancer cells in the TDTS did not correspond to the tumor tissue and is in need 
of optimization. 
COX-2 positive cells in both 3D models were found in the hypoxic area at the border of the 
necrotic core and the proliferative zone, an area known to harbor quiescent and senescent 
cells. COX-2 expression is known to be induced by hypoxia (Zhao et al., 2012). Since 
chemo- and radiotherapy targets actively dividing cells, senescent and quiescent cells within a 
tumor are thought to be more resistant. The COX-2 expressing cells in the MCTS might 
represent a chemo resistant cell population and yet another interesting therapeutic target for 
combinational studies. However this needs to be further assessed.  
Since the fibroblast population in the MCTS expressed mPGES-1 we evaluated the 
combinational effect of selective mPGES-1 inhibition and the conventional chemotherapeutic 
drugs doxorubicin and vincristine commonly used in the treatment of high-risk 
neuroblastoma. Single treatment of the mPGES-1 inhibitor CIII reduced PGE2 levels and 
significantly reduced the cell viability in the MCTS. mPGES-1 inhibition with CIII 
augmented the cytotoxic effect of doxorubicin or vincristine. This underlines the advantage of 
combining drugs mainly targeting the proliferative malignant cells with stroma-targeted 
drugs. 
Previous studies have described neuroblastoma to possess an immunosuppressive 
microenvironment. PGE2 is known to favor tumor-promoting M2 polarization and 
differentiation of monocytes. In paper II we observed a higher infiltration of M2 
macrophages in high-risk tumors and in paper III we could induce a shift in M1/M2 
macrophage polarization supporting anti-tumor immunity by mPGES-1 inhibition. To 
evaluate if MCTS could be used as a model to study inflammatory activity in neuroblastoma 
and if inhibition of PGE2 production could potentiate an induced anti-tumor immunity 
response, peripheral blood mononucleated cells (PBMCs) were added to the MCTS. By 
inducing PBMCs with INFγ and LPS, we aimed to simulate an anti-tumor Th1 response and 
classical M1 activation. Analysis of supernatants from MCTS grown with activated PBMC 
revealed an M1 polarization cytokine/chemokine profile compared to non-activated PBMCs. 
IHC analysis showed expression of the macrophage marker CD68 in MCTS with both 
activated and non-activated PBMCs. The M2 polarization marker CD163 however, was 
exclusively expressed in MCTS grown with non-activated PBMCs. Addition of activated 
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PBMCs significantly reduced the growth of MCTS and mPGES-1 inhibition significantly 
enhanced this growth reduction. 
Taken together, establishment of a three dimensional tumor model containing both neoplastic 
and stromal cells more accurately reflect the complex cell interaction and heterogeneity of 
neuroblastoma pathobiology than conventional two-dimensional monocultures. This model 
provides a relevant in vitro tool for screening of stroma targeting drugs in combination with 
established cancer therapies. 
 
 
Figure 9. (A) Illustration of the local tumor milieu that is simulated in a multicellular tumor sphere. (B) Model 
of immune activation. Simulation of Th1 immune response with IFNγ and LPS resulting in induction of the anti-
tumoral M1 polarization of monocytes. CIII treatment inhibits the immunosuppressive properties of PGE2 
known to promote M2 polarization of macrophages.  
 
5 CONCLUSION AND FURTHER PERSPECTIVES 
During the 21st century there have been an impressive increase in survival of children with 
neuroblastoma due to intensified therapy with combination of chemotherapy, surgery and 
radiotherapy. However, despite this progress the prognosis for children within the high-risk 
group are still poor and these children often suffers from severe side effects. In addition, in 
the last decades the impact of the conventional therapies on survival seems to have reached a 
plateau. This calls for the need of improved biological understanding and novel targeted 
therapies that improve survival with fewer side effects. In this thesis we provide a deeper 
biological understanding of the complex tumor promoting cell interactions conducted via 
PGE2 within the neuroblastoma microenvironment.  
In paper I we demonstrate that neuroblastoma cells abundantly express all EP receptors and 
that PGE2 results in activation of downstream cancer survival signaling cascades. This 
suggests that selective inhibition of PGE2 signaling by receptor antagonists could provide a 
therapeutic approach. However, PGE2 signaling is complex, conducted via several receptors 
expressed by several cells within the tumor and are known to be trans-activated via other 
receptors. Consequently, selective EP receptor targeting is difficult. Even if one of the EP 
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receptors will be proven to play a more important role in cancer growth, single receptor 
targeting might not be sufficient to improve patient outcome.  
 
In paper II we reveal an active COX/mPGES-1/PGE2 pathway in 11q-deletd neuroblastomas 
with high expression o mPGES-1 and low 15-PGDH expression.  
In addition, we demonstrate high-risk neuroblastoma tumors to present an 
immunosuppressive microenvironment and that cancer-associated fibroblasts play a role in 
the complex tumor-stroma interactions and might promote anti-cancer inflammation via 
PGE2 production. These results imply mPGES-1 inhibition as a therapeutic approach in high-
risk neuroblastoma. 
 
In paper III we show that pharmacological mPGES-1 inhibition modulates the 
microenvironment and significantly inhibits tumor growth, shown both in 11-q deleted 
neuroblastoma xenografts and in an aggressive MYCN driven transgenic model. We 
therefore conclude that a seemingly non-toxic treatment targeting non-malignant cells in the 
inflammatory tumor-promoting microenvironment may constitute a novel clinical therapeutic 
approach for children with high-risk neuroblastoma. 
 
In this thesis the importance of stromal cells within the neuroblastoma microenvironment has 
become evident. There is accumulating evidence of a strong link between the tumor 
microenvironment on drug response and disease progression in neuroblastoma. In paper IV 
establishment of a model aiming to mimic the microenvironment of neuroblastoma enables 
pharmacological mPGES-1 inhibition in combination with conventional cancer therapies in 
vitro, targeting both malignant cells and stromal cells. mPGES-1 inhibition enhances the 
cytotoxic effect of established chemotherapeutic drugs. 
Taken together we show that pharmacological inhibition of mPGES-1 in the neuroblastoma 
microenvironment provides a promising therapeutic alternative to recapitulate the potent 
effect of COX inhibition on tumor growth without the severe side effects. Since no signs of 
toxicity were observed in mice treated with an mPGES-1 inhibitor over a longer period of 
time we propose mPGES-1 inhibition for future clinical applications as an adjuvant treatment 
or long-term maintenance treatment for neuroblastoma high-risk patients. 
A wide verity of potential therapeutic targets has been proposed in the post-genomic era. 
However, the therapeutic effect of novel drugs in the cancer field still relies on tumor cell 
lines cultured in two-dimensions. As a result the approval rate of targeted therapies is only 5-
7%. There is an urgent need to improve the preclinical cancer models so that they mimic as 
close as possible the malignat cancers seen in patients. In paper IV we show that three 
dimensional multicellular models provides a tool that more closely recapitulates in vivo 
features of neuroblastoma opening up for further exploration of the complex cellular 
interactions in the microenvironment and screening of drugs targeting tumor-stroma 
interactions in vitro. Three-dimensional in vitro models of neuroblastoma hopefully will 
improve the selection of therapeutic drugs for both animal testing and clinical trial. 
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Personalized medicine is an emerging field in neuroblastoma research and there is an 
increased interest in using primary cancer cells and tissue for drug screening. Establishment 
of patient derived xenografts as preclinical models for neuroblastoma have been successful 
with retained features of patient tumors, especially patient derived orthotopic xenografts 
seems to be a promising model since they give rise to metastasis in contrast to cell-line 
derived xenografts (Braekeveldt and Bexell, 2017; Braekeveldt et al., 2016). However, these 
models lack a normal immune system impeding immune therapy trials, another successful 
and growing field in pediatric cancers (Kopp and Katsanis, 2016). This has led to the 
development of humanized mouse models where mice are engrafted with human 
hematopoietic stem cells resulting in a functional human immune system. However these 
mouse models are costly and in addition the access to patient material is limited.  
In conclusion, the complex interaction within the neuroblastoma microenvironment is an 
important filed of investigation in the search of novel therapeutic targets that can improve 
survival and reduce severe side effects. In order to do so we need reliable preclinical models.  
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